Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9853509 | 0.68 | TSHR (0.50) | ALDH1A1L3MBTL1TSHRMAPK1KDM4E | |
| SCHEMBL1877238 | 0.67 | TSHR (0.33) | ALDH1A1L3MBTL1TSHRMAPK1NPSR1 | |
| SCHEMBL28280483 | 0.66 | CYP2C19 (0.61) | ALDH1A1TSHRNPSR1CYP2C19AOC3 | |
| SCHEMBL3765064 | 0.64 | CHRM2 (0.35) | ALDH1A1TSHRMAPK1NPSR1KDM4E | |
| SCHEMBL7720132 | 0.64 | MAPT (0.43) | ALDH1A1TSHRKDM4EMAPTAOC3 | |
| SCHEMBL9463538 | 0.63 | HTR1D (0.46) | ALDH1A1L3MBTL1TSHRCYP2C19AOC3 | |
| SCHEMBL10660626 | 0.61 | TSHR (0.54) | ALDH1A1TSHRMAPK1KDM4EGAA | |
| SCHEMBL400749 | 0.61 | TSHR (0.54) | ALDH1A1TSHRMAPK1KDM4EGAA | |
| SCHEMBL112375 | 0.60 | TSHR (0.58) | ALDH1A1TSHRMAPK1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL7899272 | 0.60 | TSHR (0.52) | ALDH1A1TSHRMAPK1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| EP-2231641-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009081105-A2 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | ALDH1A1 4276/4885L3MBTL1 3240/4885TSHR 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.